CLINICAL_TRIALS trial_result · 2015-12-01

Clinical Trial Update: Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer [Phase 2]

Phase 2 study of AMG 479 as second-line therapy for recurrent platinum-sensitive ovarian cancer has completed; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Translational Research in Oncology | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2015-12-01